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Abstract
Objective—To determine the impact of endometriotic lesion removal on local and systemic 
inflammation.
Design—Multiplex cytokine analysis on samples from endometriosis patients before surgery, 2 
weeks after surgery, and 3 months after surgery.
Setting—Academic teaching hospital and university.
Patient(s)—A total of 43 endometriosis patients before and after excision of lesions by means of 
laparoscopic surgery, and 25 normal women.
Intervention(s)—None.
Main Outcome Measure(s)—Plasma, eutopic and ectopic tissue, and peritoneal fluid cytokine 
levels.
Result(s)—Compared with presurgery plasma samples, levels of granulocyte-macrophage 
colony-stimulating factor (GM-CSF), interleukin (IL) 2, IL-8, and IL-10 decreased significantly 
by 2 weeks after surgery in endometriosis patients. Interestingly, levels began to rise at 3 months 
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after surgery in most cases. In tissue, levels of GM-CSF and IL-15 were lower in eutopic tissue, 
while levels of basic fibroblast growth factor, interferon-inducible protein 10, IL-1 receptor 
antagonist, granulocyte colony–stimulating factor, macrophage inflammatory protein 1β, IL-7, and 
IL-5 were higher in eutopic than in ectopic tissue. In peritoneal fluid, levels of IL-5 and IL-12 
were higher in early versus advanced stages of endometriosis. Compared with normal women, 
plasma from endometriosis patients had higher levels of inflammatory cytokines.
Conclusion(s)—Endometriotic lesion removal significantly alters the inflammatory profile both 
locally and systemically in women with endometriosis. Our findings indicate that ectopic lesions 
are the major drivers of systemic inflammation in endometriosis. The transitory nature of the 
change may reflect the recurrence of the condition and the influence of systemic factors in its 
onset.
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Endometriosis is a gynecologic condition characterized by the presence and growth of 
endometrial tissue outside of the uterus, predominantly in the peritoneal cavity. The 
condition is thought to affect ~5%–10% of women of reproductive age, but is present in up 
to 70% of women with infertility or pelvic pain (1, 2). Although the symptoms are 
debilitating in many patients, endometriosis can be asymptomatic, and symptoms do not 
always correlate to the severity of the disease. The associated burden on the affected patients 
arises mainly due to pain and subfertility for which the limited treatment options often target 
the symptoms rather than the underlying condition (3). The cause and mechanism of 
progress of endometriosis are yet unknown. Retrograde menstruation is the most accepted 
theory on the pathogenesis of endometriosis, although the predominance of the phenomenon 
suggests that additional susceptibility factors must be present for the development of the 
condition.
The growth of endometriotic lesions seems to depend on an inflammatory environment and 
an aberrant immune response, both of which can contribute to the growth of ectopic tissue 
via the stimulation of other aggravating processes (2). Previous studies have identified the 
overexpression of proinflammatory cytokines and growth factors in the peritoneal fluid (PF) 
and tissues of endometriosis patients, while simultaneously finding decreased levels of 
antiinflammatory cytokines (4). Endometriosis is also characterized by estrogen dependence 
and progesterone resistance (5, 6), meaning that lesions manage to evade the cyclic controls 
that regulate normal endometrial function. The local production of these hormones has been 
observed in endometriosis patients and seems to be promoted by aberrant cytokine 
expression (7, 8). Additionally, the sites of ectopic endometrial growth have been shown to 
undergo significant immune infiltration (9–11), likely due to the higher levels of chemokines 
expressed in the peritoneal cavity of these patients (12). Compared with normal women, 
those with endometriosis not only have altered numbers of infiltrating immune cells, but 
these cells often exhibit reduced cytotoxicity (13–15), meaning that endometriosis patients 
have an impaired capacity to clear the ectopic endometrial fragments. This aberrant immune 
environment not only exacerbates the inflammation, but also helps to promote the growth 
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and vascularization of lesions via dysregulated expression of growth factors and angiogenic 
cytokines (16–18).
Because cytokines are the signaling molecules of the immune system, aberrant cytokine 
signaling is both an indicator and a regulatory agent of these processes. The complexity of 
the molecular pathways that regulate inflammation and the immune response presents a 
great challenge to researchers, with most studies highlighting the role of one or several key 
regulatory factors, and none providing a definitive basis to the pathogenesis of 
endometriosis. Previous studies also fail to elucidate whether local inflammation is a trigger 
or a consequence of endometrial lesion establishment and growth. In the present study, we 
sought to determine the contribution of the lesions to the local and systemic inflammatory 
profile in women with endometriosis. We examined the profile of 26 cytokines in the 
plasma, eutopic and ectopic tissue, and PF of women with endometriosis. We followed 
endometriosis patients who underwent surgery to remove the lesions and measured the levels 
of cytokines before surgery, 2 weeks after surgery, and 3 months after surgery. To our 
knowledge, this is the first report to examine the impact of endometriotic lesion removal on 
local and systemic cytokine levels. We also compared plasma samples from endometriosis 
patients with those of normal women, to determine if there were relevant differences in their 
cytokine profiles.
MATERIALS AND METHODS
Ethics Statement
Ethics approval for this study was obtained from the Greenville Health System (South 
Carolina) and the University of North Carolina (Chapel Hill), and written informed consent 
from every subject was obtained before sample collection and storage (IRB protocol no. 
Pro00000993).
Sample Collection, Patient Characteristics, and Inclusion/Exclusion Criteria
Samples were obtained from 43 patients with visually diagnosed endometriosis undergoing 
resection of lesions because of infertility or pain at Greenville Hospital. Patients from whom 
we obtained plasma samples (n = 19) were further subgrouped into early (stages I and II; n = 
14) and advanced (stages III and IV; n = 5) disease categories. Subjects with endometriosis 
were recruited and consented at the preoperative visit. Subjects were recruited if they were 
undergoing diagnostic laparoscopy and included if endometriosis was clinically identified at 
the time of surgery. All of the endometriosis patients included in this study underwent 
surgery. Stage of endometriosis was assigned by the surgeon based on the revised American 
Society for Reproductive Medicine criteria (19). Blood was drawn before surgery for 
collection of plasma in an EDTA-containing vacuum tube. Endometrial biopsy was 
performed after uterine lavage and cervical brushings. Laparoscopy was performed as part of 
the diagnostic evaluation for infertility and/or pelvic pain. Before resection or any surgical 
ablation or hysteroscopy, PF was obtained with the use of a cannula and syringe. At the 2-
week postoperative visit and at 3 months, venous blood sampling was repeated. Women on 
oral contraceptives or injectable progestins were excluded from the study. Only women of 
reproductive age without hormone treatment in the preceding 3 months were included. We 
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also obtained plasma samples from 25 apparently healthy normally cycling women 
volunteers aged 20–36 years from the University of North Carolina School of Medicine. 
They were recruited by advertising in the local media and screened according to study 
guidelines. Clinical information was obtained with the use of a standardized questionnaire 
reviewed by the study coordinator. None of the healthy volunteers had signs or symptoms of 
endometriosis or infertility-related problems.
Protein Extraction
Eutopic and ectopic samples obtained from endometriosis patients were used for total 
protein extraction. Briefly, tissue samples were placed in 1.5-mL microcentrifuge tubes 
containing 200 µL phosphate buffered saline solution. The protease inhibitor aprotonin was 
added to each tube (2 µL; Sigma Aldrich). The tissue was homogenized with the use of a 
rotorstator homogenizer on ice. The samples were then centrifuged at 4°C and the supernate 
collected. The samples were diluted to a protein concentration of 5 µg/µL with the use of 
DNAse/RNAse–free water and subsequently stored at −80°C. Protein concentrations were 
determined with the use of a protein assay (Bio-Rad).
Cytokine Multiplex Analysis
A single panel of a commercial multiplex assay (Luminex xMAP laser bead technology) 
available from Bio-Rad was used for analysis of selected cytokines/chemokines involved in 
the inflammatory and angiogenic pathways: platelet-derived growth factor (PDGF) BB, 
Eotaxin, basic fibroblast growth factor (bFGF), granulocyte colony–stimulating factor (G-
CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN) γ, 
interferon-inducible protein (IP) 10, monocyte chemotactic protein (MCP) 1, macrophage 
inflammatory protein (MIP) 1α, MIP-1β, Regulated on activation, normal T expressed and 
secreted (RANTES), tumor necrosis factor (TNF) α, vascular endothelial growth factor 
(VEGF), interleukin (IL) 1β, IL-1 receptor antagonist (IL-1Ra), IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-9, IL-10, IL-12, IL-13, and IL-15. Briefly, color-coded polystyrene beads were 
coupled with capture antibodies for each respective target cytokine. Plasma samples were 
aliquotted into 15 µL and diluted four times with the use of the provided sample diluent. 
Diluted plasma and protein samples were preincubated with 50 µL antibodies conjugated to 
magnetic beads in a 96-well plate. The plate was covered and incubated in the dark at room 
temperature on a shaker for 30 minutes. The plate was washed three times with the wash 
buffer provided with the kit. After diluting 25 µL detection antibody in detection antibody 
diluent, the plate was incubated in the dark at room temperature on a shaker for 30 minutes. 
The plate was washed three times in wash buffer, and 50 µL streptavidin-phycoerythrin 
fluorescent conjugate was added to the wells. The plate was incubated for 10 minutes before 
being washed, and then a Bio-Plex 200 System was used to read it. The standards for this 
assay were provided by the manufacturer as a lyophilized cocktail of proteins and were run 
for each individual target analyte. The cocktail was then serially diluted and standard curve 
dilutions were run within the assay. Increasing fluorescent intensity signals are read as 
fluorescence intensity values, which are in direct proportion to protein bound to the specific 
analyte bead population. Observed concentration for each target analyte was calculated 
against standard curve regression, and values were recorded in units of pg/mL. Cytokines 
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were quantified through the detection of conjugate, which is in direct proportion to the 
amount of the target analyte.
Statistical Analysis
Statistical analysis was performed with the use of Sigma Stat 3.5. Plasma samples from 
endometriosis patients (n = 19) were pooled as well as further subgrouped into early (stages 
I and II; n = 14) and advanced (stages III and IV; n = 5) disease categories. Plasma samples 
from normal subjects (n = 25) were pooled as well as subgrouped by menstrual cycle phase 
into secretory phase (n = 9) and proliferative phase (n = 9). For the subgrouping, we 
excluded seven samples for which we did not know the menstrual cycle phase. Plasma data 
from endometriosis patients were analyzed with the use of one-way repeated-measures 
analysis of variance (ANOVA) and Tukey post hoc test, or with the use of Friedman ANOVA 
on ranks for nonparametric data. Paired t test or Wilcoxon signed rank test was used to 
analyze paired tissue data. Plasma data comparing endometriosis and normal subjects were 
analyzed with the use of Kruskal-Wallis one-way ANOVA and Dunn post hoc test. 
Peritoneal fluid data were analyzed with the use of one-way ANOVA or Friedman ANOVA 
on ranks. A P value of <.05 was considered to be significant.
RESULTS
Excision of Lesions Causes a Significant but Transient Shift in Systemic Cytokine Levels
To evaluate the impact of lesion removal on the systemic circulating levels of cytokines, we 
compared plasma samples obtained from endometriosis patients before surgery, 2 weeks 
after surgery, and 3 months after surgery. We found that the levels of GM-CSF, IL-2, IL-8, 
and IL-10 decreased significantly after removal of lesions (Fig. 1A). However, post hoc 
analysis revealed that this difference was significant only when comparing presurgery versus 
2-week postsurgery samples. At 3 months after surgery, the levels of these cytokines were 
found to increase close to the levels measured before surgery. An overall trend was noted 
where cytokine levels decreased after surgery in all except four cytokines, although the 
changes did not achieve statistical significance. The exceptions were IL-12 and IL-13, which 
remained the same after surgery and were then increased slightly at 3 months after surgery. 
IP-10 and RANTES seemed to have a delayed decrease: They showed a slight increase 2 
weeks after surgery and then a decrease at 3 months after surgery.
When the data were stratified by disease stage, GM-CSF levels were found to decrease 
significantly after surgery in advanced endometriosis patients (stages III–IV), whereas the 
decrease was not statistically significant in early endometriosis patients (stages I–II). 
However, post hoc analysis revealed that the differences seen in the advanced stage patients 
were not significant for any particular pairwise comparison, despite having an overall P 
value (P=.039) that was significant (Fig. 1B). These results indicate that the decrease in GM-
CSF levels was more pronounced in advanced-stage patients than in early-stage patients. No 
differences were detected for any other cytokine.
When data were stratified by disease stage and time point, RANTES levels were found to be 
lower in presurgery samples from early-stage patients (stages I–II) compared with 
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presurgery samples from advanced-stage patients (stage III–IV of endometriosis). This 
means that before surgery, early-stage patients had lower blood levels of RANTES than 
advanced-stage patients. After surgery, these differences disappeared. No differences were 
found in 2-week or 3-month postsurgery samples. Also, no differences were observed for 
any other cytokine (Fig. 1C).
Levels of Inflammatory Cytokines are Predominantly Higher in Endometriosis Patients 
than in Normally Cycling Women
We performed several comparisons on plasma samples to determine if there were differences 
between endometriosis patients and normal women and to evaluate the potential influence of 
such differences in the pathogenesis of the condition. We found 19 different cytokines to be 
differentially expressed in endometriosis patients compared with normal subjects (Table 1). 
Interestingly, the levels of 18 of these cytokines were higher in endometriosis patients 
compared with normal subjects. MCP-1 was the only cytokine expressed at lower levels in 
endometriosis patients compared with normal subjects, but only when comparing 
postsurgery samples. When comparing presurgery levels of MCP-1, no significant difference 
was observed.
When endometriosis data were stratified by disease stage, we found that the levels of 11 
cytokines were higher than in normal women (Supplemental Table 1, available online at 
www.fertstert.org). For all 11 cytokines, the levels were higher only in advanced-stage 
presurgery samples compared with normal samples, meaning that before surgery, advanced-
stage patients had significantly higher levels of these cytokines than normal women, and 
after surgery the differences disappeared. These differences were not observed in early-stage 
patients. However, within these 11 cytokines, G-CSF and IL-7 were found to be more highly 
expressed in early-stage patients at all time points compared with normal women. This 
means that endometriosis patients had higher levels of G-CSF and IL-7 than normal women 
regardless of the surgery.
Finally, we compared endometriosis samples with normal samples stratified by phase of 
menstrual cycle (secretory or proliferative phase), to determine if menstrual cycle 
fluctuations would influence the comparison (Supplemental Table 2, available online at 
www.fertstert.org). The results mostly agree with the findings presented in Table 1. We 
found that 12 out of 18 cytokines were more highly expressed in endometriosis patients at 
all time points compared with all normal patients. The remaining six cytokines had varying 
results. Levels of IL-1β and IL-13 were higher in presurgery and 3-month postsurgery 
samples compared with normal samples from women in the proliferative phase, but not the 
secretory phase. Eotaxin levels were higher in 2-week postsurgery samples compared with 
normal proliferative-phase samples only. IL-2 levels were higher in presurgery samples 
compared with normal proliferative samples.
Inflammatory Cytokines are Differentially Expressed and Related to Disease Stage in 
Eutopic versus Ectopic Endometrium
To evaluate the differences between eutopic and ectopic endometrium, we compared 
cytokine levels between matched eutopic and ectopic tissue obtained from the same patient 
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before surgery (Fig. 2). Differential expression of nine cytokines was detected in eutopic 
compared with ectopic tissue. Levels of bFGF, IP-10, IL-1Ra, G-CSF, MIP-1β, IL-7, and 
IL-5 were significantly higher in eutopic than in ectopic tissue. Conversely, levels of GM-
CSF and IL-15 were lower in eutopic compared with ectopic tissue.
When samples were stratified by disease stage, we detected differential expression of 
IL-1Ra, IL-5, IL-7, IL-9, IL-15, bFGF, G-CSF, GM-CSF, IP-10, MIP-10, and TNF-α when 
comparing eutopic versus ectopic tissue in early stage patients. When comparing eutopic and 
ectopic tissues in advanced-stage patients, only IL-2 was found to be differentially expressed 
in eutopic versus eutopic tissue (Fig. 3). No differences were observed for the other 
cytokines.
When tissue samples were stratified by disease stage and tissue type, levels of PDGF-BB, 
IL-4, IFN-γ, IL-9, bFGF, and TNF-α were found to be higher in the early-stage eutopic 
samples than in advanced-stage eutopic samples (Supplemental Fig. 1, available online at 
www.fertstert.org). When comparing early- versus advanced-stage ectopic samples, GM-
CSF levels were higher in early-stage ectopic samples than in advanced-stage ectopic 
samples. Conversely, ectopic samples had lower G-CSF levels in the early-stage samples 
than in the advanced-stage samples, but those differences were not seen in the eutopic 
samples. No differences were observed for the other cytokines.
Peritoneal Fluid Expresses High Levels of Inflammatory Cytokines that Change with 
Disease Stage
Peritoneal fluid samples from endometriosis patients were compared to evaluate the impact 
of disease stage on local cytokine levels (Supplemental Fig. 2, available online at 
www.fertstert.org). IL-5 levels changed significantly when comparing disease stages I, II, 
and III, but post hoc tests revealed that differences were not significant despite a significant 
overall P value. IL-12 was also found to change significantly, but only when comparing 
stage III versus stage I, which could indicate that a significant change occurs in the transition 
from early to advanced stages. The cytokine profile of PF in these patients was significantly 
proinflammatory, containing high levels of inflammatory cytokines (Supplemental Fig. 2).
Correlation between Inflammatory Cytokine Levels Across Different Tissues
To determine whether there was an association between cytokine levels in different tissues, 
we performed a correlation analysis to compare cytokine levels in plasma, tissue, and PF 
(Supplemental Table 3, available online at www.fertstert.org). We found significant 
correlations between plasma and ectopic tissue. We found a positive correlation when 
comparing VEGF levels in presurgery plasma versus ectopic tissue (0.536; P=.0219). When 
comparing 2-week postsurgery plasma versus ectopic tissue, we found a positive correlation 
for IL-5 (0.52; P=.0269). When comparing 3-month postsurgery plasma versus ectopic 
tissue, we found a positive correlation for IP-10 (0.478; P=.0451) and G-CSF (0.499; P=.
0352) and a negative correlation for GM-CSF (−0.529; P=.024). Finally, when comparing 
eutopic versus ectopic tissue, we found a significant negative correlation for IL-4 (−0.658; 
P=.00301).
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DISCUSSION
This study is the first to report that the excision of endometriotic lesions produces a 
measurable systemic shift in the inflammatory cytokine profile of patients with 
endometriosis. Inflammation is one of the defining features of endometriosis and has been 
shown to be a major driving factor for the condition. Our findings provide striking evidence 
that endometriotic lesions are not simply a result of the condition, but rather act as major 
regulators and promoters of inflammation, thus aiding the progress of endometriosis at a 
local and systemic level. Lesion removal resulted in a measurable shift in cytokine levels 
that extended beyond the local pelvic environment. All except two of the plasma cytokines 
exhibited a trend of decrease after surgery. Although only four were statistically significant, 
this trend further supports the idea that endometriotic lesions are the major drivers of 
inflammation in these patients. Importantly, at 3 months after surgery, cytokine levels 
seemed to begin to return to their initial levels. The fact that the change was transient 
suggests that either surgery was unable to remove all traces of the lesions or that additional 
factors are involved in the onset of endometriosis.
In the pooled plasma analysis, we detected a significant decrease in circulating levels of 
GM-CSF, IL-2, IL-8, and IL-10 after removal of lesions, which suggests that in these 
patients, systemic inflammation is driven locally by the ectopic lesions through several 
mechanisms. IL-10 is mostly known as a key regulatory cytokine essential for the 
dampening and resolving of inflammation during the immune response. Our findings 
support previous reports that IL-10 is indeed overexpressed in the serum endometriosis 
patients (20) and that it is capable of promoting lesion growth by locally suppressing the 
immune cells that would help clear the endometrial fragments (13, 20). Because IL-10 can 
inhibit IL-2 and GM-CSF, the increased levels of IL-10 could reflect an attempt to inhibit 
the high levels of IL-2 and GM-CSF observed in these patients. IL-2 is normally secreted by 
activated T cells and natural killer cells and is an important regulator of self tolerance (21). 
The increased expression of IL-2 in plasma may point to the inability of these patients to 
regulate inflammation and could indicate a predisposition to autoimmune characteristics. 
GM-CSF is usually secreted in response to other inflammatory cytokines, such as IL-1, and 
seems to act locally, mediating the recruitment and activation of macrophage-lineage cells 
(22). We speculate that the high circulating levels of GM-CSF observed in these patients 
simply reflect an inability to regulate the inflammation at the local level, as supported by the 
immediate postsurgery decrease in circulating GM-CSF levels. Furthermore, the decrease in 
GM-CSF levels after surgery was significant in advanced-stage patients and not in early-
stage patients. Given that GM-CSF is mostly locally acting, lesions that are larger and more 
established would be necessary for circulating levels to be influenced. Additionally, ectopic 
tissue was found to express higher levels of GM-CSF than eutopic tissue, further indicating 
that ectopic lesions are driving the aberrant expression of this cytokine. Meanwhile, IL-8 is a 
chemotactic and angiogenic factor previously shown to contribute to neutrophil recruitment 
and blood vessel formation in endometriotic lesions (23, 24). High levels of IL-8 have 
previously been detected in the PF and serum of women with endometriosis (25, 26), which 
supports our findings. However, the fact that IL-8 levels decreased immediately after surgery 
suggest that the ectopic lesions were the main drivers of these up-regulated levels. IL-8 is 
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also a potent chemotactic factor for basophils and GM-CSF–primed eosinophils (27). Given 
the high expression of GM-CSF in both plasma and ectopic tissue, IL-8 would aggravate 
immune infiltration at the lesion sites. Endometrial cells have been shown to produce IL-8 
and to have increased expression of IL-8 and cyclooxygenase (COX) 2 under stimulation of 
IL-17 in vitro (28), meaning they can stimulate local blood vessel formation. Our group 
recently confirmed that IL-17A is expressed in the eutopic and ectopic endometrium of 
women with endometriosis, and that IL-17A stimulation of cultured endometrial cells 
induces the production of VEGF, G-CSF, PDGF-AA, and stromal cell–derived factor 1 (23), 
which could be a mechanism by which ectopic lesions increase IL-8 production.
To further support the impact of ectopic lesions on systemic inflammation, we detected 
lower levels of RANTES in the plasma of early-stage patients compared with advanced-
stage patients. RANTES is a chemokine involved in the activation and recruitment of 
immune cells to sites of allergic reaction (29). Given that RANTES is a locally acting 
chemokine that is also involved in late-phase inflammatory response, we speculate that it 
may play a more active role in advanced stages of disease, where it would be produced by 
the larger ectopic lesions and promote immune cell infiltration. Elevated levels of RANTES 
have been previously detected in the PF and eutopic and ectopic tissues of women with 
endometriosis (30, 31), and its production can be induced by IL-1β (32). Our analysis of 
eutopic and eutopic tissue indicates that IL-1 expression is dysregulated at the lesion sites, 
further supporting previous reports. The combined effect of these factors is a local 
proangiogenic microenvironment aggravated by unresolved inflammation that leads to a 
systemic inflammatory response. We also found these results to be supported when we 
compared plasma from endometriosis patients with that from normal women. Of the 19 
cytokines that were statistically significant, 18 were higher in endometriosis patients 
compared with normal women, including IL-2, IL-8, IL-10, and RANTES. These results 
indicate that these cytokines are not only dysregulated in endometriosis patients, but also are 
expressed aberrantly compared with normal subjects. The remaining cytokines have been 
shown in previous reports to be dysregulated in women with endometriosis, as extensively 
reviewed elsewhere (33, 34). In our analysis of matched eutopic and ectopic tissue, we found 
differential expression of nine cytokines, bFGF, IP-10, IL-1Ra, G-CSF, MIP-1β, IL-7, IL-5, 
GM-CSF, and IL 15, which further supports the idea that this local aberrant cytokine profile 
is likely driving the systemic inflammation via a positive feedback cycle. Most of these 
cytokines were more highly expressed in the eutopic than ectopic endometrium. The only 
exceptions were GM-CSF and IL-15, which were more highly expressed in ectopic tissue. 
As we previously mentioned, GM-CSF may contribute to the increased inflammatory 
response, particularly by inducing the differentiation of granulocytes and macrophages or 
their proliferation at lesion sites.
Conversely, IL-1Ra was more highly expressed in eutopic than in ectopic endometrium. 
Furthermore, after data stratification, we found that this difference was most significant 
when comparing matched tissue in early-stage patients, not in advanced-stage patients, 
which may reflect local dysregulation of IL-1 signaling and an inability to control 
immunerelated inflammation at an early stage. The IL-1 family, a known key regulator of the 
inflammatory response, has been found to be aberrantly expressed in women with 
endometriosis. Active endometriotic lesions seem to have increased expression of the IL-1 
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type I receptor (35), whereas expression of the decoy IL-1 type II receptor is decreased in 
the normal endometrium of endometriosis patients compared with normal women (36). 
These results point to a severely impaired regulation of the proinflammatory signaling of 
IL-1 in women with endometriosis. We detected higher levels of IL-1β, IL-1Ra, and IL-6 in 
endometriosis patients than normal women, which supports the notion that there is 
dysregulation of IL-1 signaling in these patients. For example, IL-1 can induce secretion of 
IL-6 by fibroblasts, endothelial cells, and circulating monocytes (37) and can stimulate IL-8 
secretion by endometriotic cells (24). The decreased expression of IL-1Ra in ectopic tissue 
would leave IL-1 unregulated and able to promote IL-8 production, as was found in the 
plasma of patients with endometriosis in this study. IL-6 has been shown to stimulate the 
secretion of VEGF in isolated peritoneal macrophages and neutrophils from mice (38) and 
human cell lines (39). Also, high levels of IL-6 have been found in the PF (40) and both 
eutopic and ectopic endometrium of endometriosis patients compared with normal women 
(41). The latter study (41) also reported higher levels of IL-1β in the endometrium of these 
patients, which likely further induces local IL-6 secretion. IL-1β has also been shown to 
induce neutrophil migration to the peritoneal cavity of rats, and such migration was 
dependent on macrophages and mast cells (11). Local inflammation is likely sustained by 
the immune infiltration observed in the pelvic environment of endometriosis patients.
Inflammation can be further aggravated by local production of hormones promoted by 
aberrant expression of cytokines. For example, TNF-α was one of the cytokines we found to 
be more highly expressed in endometriosis patients compared with normal subjects. IL-1 
and TNF-α are able to induce the expression of COX-2, which mainly produces 
prostaglandin E2 (PGE2). PGE2 is not only capable of self-induction via up-regulation of 
COX-2, but can induce aromatase P450 production, which is the key regulatory enzyme in 
the biosynthesis of estrogens (8). COX-2 has been shown to be overexpressed in the ectopic 
tissue of patients with endometriosis (42, 43). Furthermore, IL-1Ra, which blocks the IL-1–
induced production of COX-2 in endometrial cells (44), is down-regulated in the PF of 
women with endometriosis (45), which is consistent with our findings that IL-1Ra was 
down-regulated in ectopic compared with eutopic tissue. PGE2 thus provides a mechanism 
for lesions to locally sustain the production of prostanoids and estrogens. PGE2 is also 
capable of altering the phagocytic ability of immune cells and of promoting angiogenesis via 
VEGF expression (8), further contributing to the survival of lesions in the peritoneal cavity. 
Meanwhile, IL-5 was one of the cytokines more highly expressed in eutopic versus ectopic 
tissue, particularly in early-stage patients after data stratification. IL-5 plays a major role in 
the late-phase allergic response, being produced by mast cells within allergen-challenged 
tissues (46). Based on our results, we could speculate that IL-5 plays a major role in 
promoting the local inflammation seen in endometriosis patients, and may play a more 
important role at earlier stages of disease when lesions are in the process of establishing.
MIP-1β is an inflammatory chemokine that is stimulated by IL-7. Both were more highly 
expressed in the eutopic endometrium compared with paired ectopic endometrium. IL-7 has 
been found to be an important immunostimulatory cytokine and to be overexpressed in 
inflamed tissues of patients with autoimmune diseases such as rheumatic disease (47). IL-7, 
RANTES, IL-2, and IL-10, all of which were up-regulated in plasma, are cytokines 
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associated with autoimmune conditions and may provide further support for the concept of 
endometriosis being an autoimmune condition.
Finally, the PF of endometriosis patients in this study expressed high levels of various 
cytokines, which mostly supports previous reports. The most highly expressed cytokines 
included Eotaxin, bFGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, VEGF, IL-1Ra, IL-5, 
IL-10, and IL-15. Our stage comparisons of IL-5 and IL-12 were marginally significant, so 
further analyses would be required to understand the true significance of the cytokine profile 
in the PF of these patients.
CONCLUSION
We provide new insights on the causes of a heightened inflammatory response at local and 
systemic levels in endometriosis patients. Evidence presented in this manuscript clearly 
indicates that endometriotic lesions are probably the major drivers of inflammation, because 
the removal of lesions led to significant reduction in the systemic level of several potent 
inflammatory factors. Furthermore, most of the cytokines that were dysregulated in plasma 
or tissue of endometriosis patients were also aberrantly expressed compared with normal 
subjects. Another important piece of evidence emerging from this study is the striking 
difference in the immune microenvironment of eutopic and ectopic tissues, because 
measurable differences were detected when comparing ectopic versus eutopic tissue, as well 
as the influence of different stages of disease. Although patients recruited in this study were 
free of any form of therapy for 3 months before surgery to avoid any treatment bias on the 
cytokine profiles, patients were not tracked specifically for any nonsteroidal 
antiinflammatory drug (NSAID) use, which should be taken into consideration in future 
studies. Nevertheless, our results strongly suggest that in endometriosis, an impaired ability 
to dampen the inflammatory response triggered by the endometrial fragments helps the 
condition to evolve into a chronic condition. Although our study does not conclusively 
establish whether inflammation is initiated by the lesions or vice versa, it provides a solid 
basis that surgical intervention might provide a window of opportunity to dampen 
inflammation, which would allow for therapeutic interventions, such as reducing subfertility 
and modulating conditions that permit lesion recurrence.
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FIGURE 1. 
(A) Plasma levels of granulocyte-macrophage colony-stimulating factor (GM-CSF), 
interleukin (IL) 2, IL-8, and IL-10 decreased significantly after removal of lesions. However, 
post hoc analysis revealed that this difference was significant only in pre- vs. post-op 
samples, not in pre- vs. 3-month samples. No significant differences were observed for other 
cytokines. One-way Friedman analysis of variance (ANOVA) and Tukey post hoc test; n = 
19. (B) When stratified by disease stage, plasma levels of GM-CSF were found to decrease 
significantly after surgery in advanced endometriosis patients (stages III–IV), but not in 
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early endometriosis patients (stages I–II). However, post hoc analysis revealed that these 
differences were not significant. One-way ANOVA and Tukey post hoc test; n = 14 (early 
stage); n = 5 (advanced stage). (C) When stratified by disease stage and time point, early-
stage patients had lower plasma levels of Regulated on activation, normal T expressed and 
secreted (RANTES) than advanced-stage patients. No differences were seen in early- vs. 
advanced-stage patients at later time points. No differences were observed for other 
cytokines. Bars represent the mean, and the whiskers represent the 95% confidence intervals. 
t test; n = 14 (early stage); n = 5 (advanced stage). *P<.05.
Monsanto. Cytokines in the endometriosis. Fertil Steril 2015.
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FIGURE 2. 
Differential expression of nine cytokines was detected in eutopic tissue compared with 
ectopic tissue. Levels of GM-CSF and IL-15 were lower in eutopic tissue. In contrast, levels 
of basic fibroblast growth factor (FGF-basic), interferon-inducible protein (IP) 10, IL-1 
receptor antagonist (IL-1ra), granulocyte colony–stimulating factor (G-CSF), macrophage 
inflammatory protein (MIP) 1β, IL-7, and IL-5 were higher in eutopic than in ectopic tissue. 
Other abbreviations as in Figure 1. Bars represent the mean, and the whiskers represent the 
Monsanto et al. Page 17
Fertil Steril. Author manuscript; available in PMC 2017 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
95% confidence intervals. *P<.05; paired t test or Wilcoxon signed ranked test for 
nonparametric data (n = 18).
Monsanto. Cytokines in the endometriosis. Fertil Steril 2015.
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FIGURE 3. 
When samples were stratified by stage of disease, differential expression of IL-1ra, IL-5, 
IL-7, IL-9, IL-15, FGF-basic, G-CSF, GM-CSF, IP-10, MIP-1β, and tumor necrosis factor 
(TNF) α was observed between eutopic and ectopic tissues of early-stage patients, but not in 
advanced-stage patients. Only IL-2 was found to be differentially expressed in eutopic vs. 
eutopic tissue from advanced-stage patients. Abbreviations as in Figures 1 and 2. Bars 
represent the mean, and the whiskers represent the 95% confidence intervals. *P<.05; n = 
13; paired t test or Wilcoxon signed ranked test.
Monsanto. Cytokines in the endometriosis. Fertil Steril 2015.
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